UCLA scientists test new strategy that could help fight ovarian cancer

UCLA scientists have developed a promising novel method to treat gynecologic tumors. The approach focuses on a protein called p53, which is commonly mutated in women who have high-grade serous ovarian cancer, the deadliest form of reproductive cancer. In many women with the disease, the cancer is very advanced by the time it is diagnosed and is therefore difficult to treat. The discovery was the result of a three-year study co-led by David Eisenberg and Dr. Sanaz Memarzadeh, members of the UCLA Jonsson Comprehensive Cancer Center. The findings, which were published online in the journal Cancer Cell, could ultimately lead to new targeted therapies for many other types of cancer carrying similar p53 mutations. P53 is known as the “guardian of the genome.” It prevents damaged cells from reproducing by stopping their growth until the damage is repaired or, if the damage cannot be reversed, promotes cell death. But mutations, which are found in 96 percent of patients with high-grade serous ovarian tumors, can cause p53 to form clumps, or “aggregates,” which impair the protein’s normal function. As a result, the damaged cells are able to multiply uncontrollably, which can lead to cancer. The UCLA scientists developed and tested a peptide called ReACp53, which penetrates cancer cells and prevents mutated p53 from clumping together. The technique restores normal p53 function, causing death of the ovarian cancer cells. “Our lab has worked for 15 yea...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news

Related Links:

Authors: Essel KG, Moore KN Abstract INTRODUCTION: Niraparib, an orally available selective inhibitor of poly(adenosine diphosphate-ribose) polymerase (PARP) is the first PARP inhibitor approved for use in patients with ovarian cancer who do not harbor a germline or somatic mutation in the breast cancer gene (BRCA). Overall niraparib is well tolerated and its toxicities, primarily hematologic, are manageable especially with recently released initial dose modification guidelines based on weight and baseline platelet count. The role of niraparib as maintenance following front-line platinum-based chemotherapy as well ...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
Condition:   Ovarian Carcinoma Interventions:   Drug: pegylated liposomal doxorubicin (PLD) + carboplatin (CD);   Drug: carboplatin + paclitaxel (CP) Sponsors:   Konkuk University Medical Center;   Seoul National University Hospital;   National Cancer Center, Korea;   Asan Medical Center;   The Catholic University of Korea;   Samsung Medical Center;   Chung-Ang University Hosptial, Chung-Ang University College of Medicine;   Ajou  University;   Severa...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Abstract The present paper investigates the enhancement of the therapeutic effect of Paclitaxel (a potent anticancer drug) by increasing its cellular uptake in the cancerous cells with subsequent reduction in its cytotoxic effects. To fulfill these goals the Paclitaxel (PTX)-Biotinylated PAMAM dendrimer complexes were prepared using biotinylation method. The primary parameter of Biotinylated PAMAM with a terminal HN2 group - the degree of biotinylation - was evaluated using HABA assay. The basic integrity of the complex was studied using DSC. The Drug Loading (DL) and Drug Release (DR) parameters of Biotinylated P...
Source: Acta Biochim Pol - Category: Biochemistry Authors: Tags: Acta Biochim Pol Source Type: research
Contributors : Naoki Horikawa ; Kaoru Abiko ; Tsukasa Baba ; Junzo Hamanishi ; Ryusuke Murakami ; Mana Taki ; Masayo Ukita ; Yuko Hosoe ; Ikuo Konishi ; Noriomi Matsumura ; Masaki MandaiSeries Type : Expression profiling by arrayOrganism : Mus musculusOvarian cancer is a highly aggressive female tract cancer. Anti-VEGF therapy is widely used for the treatment of ovarian cancer, however it has shown moderate impact on patient prognosis.The elucidation of mechanism of drug resistance is highly beneficial for the advances in ovarian cancer treatment. Here, we investigated gene expression profile of HM-1 tumor which were treat...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Mus musculus Source Type: research
CONCLUSIONS The present study reveals that in ovarian cancer cells, prucalopride inhibits proliferation, migration, and invasion, and induces apoptosis and autophagy, which may be regulated by the PI3K signaling pathway. These results suggest prucalopride has potential as a new drug for clinical ovarian cancer treatment. PMID: 29909423 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
New data suggest adding bevacizumab to chemotherapy may prolong PFS in patients with recurrent ovarian cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
We report a population-based cohort study using data from 99,654 adults (68.7% female), aged 55 –74 years, participating in the U.S. Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cox proportional hazards models assessed the risk of overall and cause-specific mortality, cancer incidence (excluding nonmelanoma skin cancer), and combined risk of cancer and death across categories of self-reported average lifetime alcohol intakes, with adjustment for potential confounders. During 836,740 person-years of follow-up (median 8.9 years), 9,599 deaths and 12,763 primary cancers occurred. Positive linea...
Source: PLoS Medicine - Category: Internal Medicine Authors: Source Type: research
Upregulation of microRNA-3129 suppresses epithelial ovarian cancer through CD44, Published online: 19 June 2018; doi:10.1038/s41417-018-0026-1Upregulation of microRNA-3129 suppresses epithelial ovarian cancer through CD44
Source: Cancer Gene Therapy - Category: Cancer & Oncology Authors: Source Type: research
ConclusionsEOC imposes a significant economic burden on the national healthcare system and society in Spain. Investment in better early diagnosis techniques might increase survival and patients ’ quality of life. This would likely reduce costs derived from late stages, consequently leading to a substantial reduction of the economic burden associated with EOC.
Source: The European Journal of Health Economics - Category: Health Management Source Type: research
Ovarian cancer is the second most common gynaecologic malignancy and the most common cause of death from gynaecologic cancer, especially due to diagnosis at an advanced stage, when a cure is rare. As ovarian t...
Source: BMC Evolutionary Biology - Category: Molecular Biology Authors: Tags: Research article Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Chemistry | Chemotherapy | Computers | Health | Laboratory Medicine | National Institutes of Health (NIH) | Neurology | Neurosurgery | OBGYN | Ovarian Cancer | Ovaries | Stem Cell Therapy | Stem Cells | Study | Universities & Medical Training | Women